A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world

Journal of Addiction Medicine

Volumn 8, Issue 5, 2014, Pages 315-326

  Lofwall, Michelle R ^a,b   Walsh, Sharon L ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Behavioral pharmacology; Buprenorphine; Diversion; Epidemiology; Misuse; Treatment

Indexed keywords

BUPRENORPHINE; NARCOTIC ANTAGONIST;

DRUG BIOAVAILABILITY; DRUG COST; DRUG FORMULATION; DRUG MARKETING; DRUG MECHANISM; DRUG MISUSE; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; HUMAN; INTRAVENOUS DRUG ABUSE; MEDICAL LIABILITY; OPIATE ADDICTION; OUTPATIENT; POLICY; PRACTICE GUIDELINE; PRESCRIPTION DRUG DIVERSION; PROFESSIONAL PRACTICE; REVIEW; RISK FACTOR; SOCIAL PSYCHOLOGY; TREATMENT REFUSAL; UNITED STATES; OPIOID-RELATED DISORDERS; STATISTICS AND NUMERICAL DATA;

BUPRENORPHINE; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUG DIVERSION; PRESCRIPTION DRUG MISUSE; RISK FACTORS;

EID: 84921872375     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0000000000000045     Document Type: Review

References (101)

1. Aboltins CA, Allen P, Daffy JR. Fungal endophthalmitis in intravenous drug users injecting buprenorphine contaminated with oral Candida species. Med J Aust 2005;182:427.
2. Amass L, Kamien JB, Mikulich SK. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 2001;61:173-181.
3. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA 1998; 280: 1936-1943.
4. Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007;88:75-78.
5. Alroomi LG, Davidson J, Evans TJ, et al. Maternal narcotic abuse and the newborn. Arch Dis Child 1988;63:81-83.
6. American Society of Addiction Medicine. Advancing access to addiction medications: implications for opioid addiction treatment. A project of the ASAM. Available at: http://www.asam.org/docs/advocacy/Implications-for-Opioid-Addiction-Treatment. Published 2013. Accessed July 2013.
7. Auriacombe M, Fatseas M, Dubernet J, et al. French field experience with buprenorphine. Am J Addict 2004;13:S17-S28.
8. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001;285:45.
9. Balhara Y, Jain R. A urinanalysis-based comparative study of treatment adherence on buprenorphine and buprenorphine/naloxone combination used as opioid substitution treatment. Innov Clin Neurosci 2012;9:24-29.
10. Barry DT, Moore BA, Pantalon MV, et al. Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. J Gen Intern Med 2007;22:242-245.
11. Bazazi AR, Yokell M, Fu JJ, et al. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med 2011;5:175-180.
12. Bell J. The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinician's perspective. Addiction 2010;105:1531-1537.
13. Berson A, Gervais A, Cazals D, et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 2001;34:346-350.
14. Bickel WK, Amass L, Crean JP, et al. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology (Berl) 1999;46:111-118.
15. Bloms-Funke P, Gillen C, Schuettler AJ, et al. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 2000;21:1141-1146.
16. Boyer EW, McCance-Katz EF, Marcus S. Methadone and buprenorphine toxicity in children. Am J Addict 2010;19:89-95.
17. Carrieri MP, Amass L, Lucas GM, et al. Buprenorphine use: the international experience. Clin Infect Dis 2006;43:S197-S215.
18. Cassoux N, Bodaghi B, Lehoang P, et al. Presumed ocular candidiasis in drug misusers after intravenous use of oral high dose buprenorphine (Subutex). Br J Ophthalmol 2002;86:940-941.
19. Caviness CM, Anderson BJ, de Dios MA, et al. Prescription medication exchange patterns among methadone maintenance patients. Drug Alcohol Depend 2013;127:232-238.
20. Center for Substance Abuse Research. Buprenorphine availability, diversion, misuse: a summary of the CESAR FAX Series. 2011;20(34). Available at: http://www.cesar.umd.edu/cesar/cesarfax.asp.
21. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939.
22. Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005. Treatment Improvement Protocol (TIP) Series 43. DHHS Publication No. (SMA) 06-4214.
23. Cicero TJ, Surratt HL, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag 2007;3:302-308.
24. Comer SD, Sullivan MA, Vosburg SK, et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphinemaintained intravenous heroin abusers. Addiction 2010;105:709-718.
25. Cowan A, Lewis J. Buprenorphine: Combatting Drug Abuse With a Unique Opioid. New York, NY: Wiley Liss, 1995.
26. Dart RC. 5th Annual Scientific Meeting Presentation. Evaluation of ADFs using RADARS system data. Available at: http://www.radars.org/Home2/AnnualMeeting/RADARSSystem2011AnnualMeeting.aspx. Published 2011.
27. Dasgupta N, Bailey EJ, Cicero T, et al. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med 2010;11:1078-1091.
28. Degenhardt L, Larance BK, Bell JR, et al. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. Med J Aust 2009;191:161-165.
29. Department of Health and Human Services. Department of Health and Human Services 42 CFR Part 8 RIN 0930 AA14. Available at: http://www.gpo.gov/fdsys/pkg/FR-2012-12-06/html/2012-29417.htm. Published 2012. Accessed January 2013.
30. Drug Enforcement Agency. Drug Enforcement Agency National Technical Information Service 2013 data. Available at: http://www.ntis.gov/products/dea.aspx.
31. Fiellin DA, Kleber H, Trumble-Hejduk JG, et al. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat 2004;27:153-159.
32. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006;355:365-374.
33. Forsell M, Virtanen A, Jaaskelainen M, et al. Drug situation in Finland 2010. National report to the EMCDDA by the Finnish National Focal Point. National Institute for Health and Welfare (THL). Report 39/2010. Available at: http://www.thl.fi/thl-client/pdfs/7445c896- 5bc1-4bbc-b9e3-f41be4fa94e5. Published 2010. Accessed October 2013.
34. Frauger E, Moracchini C, Le Boisselier R, et al. OPPIDUM surveillance program: 20 years of information on drug abuse in France. Fundam Clin Pharmacol 2013;27:672-682.
35. Galanter M, Dermatis H, Glickman L, et al. Network therapy: decreased secondary opioid use during buprenorphine maintenance. J Subst Abuse Treat 2004;26:313-318.
36. Gerra G, Saenz E, Busse A, et al. Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:483-489.
37. Gjersing L, Bretteville-Jensen AL. Is opioid substitution treatment beneficial if injecting behaviour continues? Drug Alcohol Depend 2013;133:121-126.
38. Goldsworthy RC, Schwartz NC, Mayhorn CB. Beyond abuse and exposure: framing the impact of prescription-medication sharing. Am J Public Health 2008;98:1115-1121.
39. Gouny P, Gaitz JP, Vayssairat M. Acute hand ischemia secondary to intraarterial buprenorphine injection: treatment with iloprost and dextran-40-a case report. Angiology 1999:50:605-606.
40. Gueye PN, Borron SW, Risede P, et al. Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicol Sci 2002;65:107-114.
41. Hakkinen M, Launiainen T, Vuori E, et al. Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. Eur J Clin Pharmacol 2012;68:301-309.
42. Havnes IA, Clausen T, Middelthon AL. 'Diversion' of methadone or buprenorphine: 'harm' versus 'helping'. Harm Reduct J 2013;10:24.
43. Herve S, Riachi G, Noblet C, et al. Acute hepatitis due to buprenorphine administration. Eur J Gastroenterol Hepatol 2004;16:1033-1037.
44. HoRC, HoEC, Tan CH, et al. Pulmonary hypertension in first episode infective endocarditis among intravenous buprenorphine users: case report. Am J Drug Alcohol Abuse 2009;35:199-202.
45. Hulse GK, Milne E, English DR, et al. Assessing the relationship between maternal opiate use and antepartum haemorrhage. Addiction 1998;93:1553-1558.
46. Jaffe JH, O'Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend 2003;70:S3-S11.
47. Johanson CE, Arfken CL, diMenza S, et al. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend 2012;120:190-195.
48. Jones HE, Kaltenbach K. Treating Women With Substance Use Disorders During Pregnancy: A Comprehensive Approach to Caring for Mother and Child. New York, NY: Oxford University Press, 2013.
49. Kakko J, Gronbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007;164:797-803.
50. Kim HK, Smiddy M, Hoffman RS, Nelson LS. Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure. Pediatrics 2012;130(6):e1700-e1703.
51. Kosten TR, Fiellin DA. Buprenorphine for office-based practice: consensus conference overview. Am J Addict 2004;13:S1-S7.
52. Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med 2011;5:254-263.
53. Larance B, Degenhardt L, Lintzeris N, et al. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing. Drug Alcohol Depend 2011a;118:265-273.
54. Larance B, Degenhardt L, Lintzeris N, et al. Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug Alcohol Rev 2011b;30:236-245.
55. Larance B, Lintzeris N, Ali R, et al. The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug Alcohol Depend 2014;136:21-27.
56. Lavonas EJ, Banner W, Bradt P, et al. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children. J Pediatr 2013;163:1377-1383, e1371-e1373.
57. Lintzeris N, Leung SY, Dunlop AJ, et al. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Drug Alcohol Depend 2013;131:119-126.
58. Lofwall MR, Havens JR. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug Alcohol Depend 2012;126:379-383.
59. Lofwall MR, Wunsch MJ, Nuzzo PA, et al. Efficacy of continuing medical education to reduce the risk of buprenorphine diversion. J Subst Abuse Treat 2011;41:321-329.
60. Lofwall MR, Wunsch MJ, Walsh SL. Pharmacy willingness to partner with office-based opioid dependence treatment providers in conducting random buprenorphine pill counts. Am J Addict 2010;19:195-196.
61. Ludlow JP, Evans SF, Hulse G. Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse. Aust N Z J Obstet Gynaecol 2004;44:302-306.
62. Marsch LA, Bickel WK, Badger GJ, et al. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing. Drug Alcohol Depend 2005;77:195-204.
63. Martin TC, Rocque MA. Accidental and non-accidental ingestion of methadone and buprenorphine in childhood: a single center experience, 1999-2009. Curr Drug Saf 2011;6:12-16.
64. McLellanAT, Lewis DC, O'Brien CP, et al. Drug dependence, a chronicmedical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284:1689-1695.
65. Mendelson J, Jones RT, Welm S, et al. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiatedependent volunteers. Psychopharmacology (Berl) 1999;141:37-46.
66. Middleton LS, Nuzzo PA, Lofwall MR, et al. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction 2011;106: 1460-1473.
67. Moratti E, Kashanpour H, Lombardelli T, et al. Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy. Clin Drug Invest 2010;30:S3-S11.
68. Morrison V. Psychoactive substance use and related behaviours of 135 regular illicit drug users in Scotland. Drug Alcohol Depend 1989;23:95-101.
69. National Bureau of Investigation. NBI of Finland. 2003. Archive ID KRP/RTP 7433/213/2003.
70. Neumark YD, Van Etten ML, Anthony JC. "Drug dependence" and death: survival analysis of the Baltimore ECA sample from 1981-1995. Subst Use Misuse 2000;35:313-327.
71. Nordmann S, Frauger E, Pauly V, et al. Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey. Pharmacoepidemiol Drug Saf 2012;21:184-190.
72. Pedapati EV, Bateman ST. Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone. Pediatr Crit Care Med 2011;12:e102-e107.
73. Pirnay SO, Megarbane B, Borron SW, et al. Effects of various combinations of benzodiazepines with buprenorphine on arterial blood gases in rats. Basic Clin Pharmacol Toxicol 2008;103:228-239.
74. Quigley J, Knudsen HK, Nuzzo PA, et al. Substance use characteristics and treatment perceptions among opioid dependent pregnant women initiating methadone treatment. J Kentucky Med Assoc 2013;111:261-265.
75. Reynaud M, Petit G, Potard D, et al. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998;93:1385-1392.
76. Rogers JM. Tobacco and pregnancy: overview of exposures and effects. Birth Defects Res C Embryo Today 2008;84:1-15.
77. Rosado J, Walsh SL, Bigelow GE, et al. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100 mg of daily methadone. Drug Alcohol Depend 2007;90:261-269.
78. Roux P, Villes V, Blanche J, et al. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management. Drug Alcohol Depend 2008;97:105-113.
79. Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health Detailed. Table 1.17A. Available at: http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/DetTabs/NSDUH-DetTabsSect1peTabs1to46-2012.htm. Published 2013. Accessed October 2013.
80. Schwartz RP, Gryczynski J, O'Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Health 2013;103:917-922.
81. Selden T, Ahlner J, Druid H, et al. Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome. Forensic Sci Int 2012;220:284-290.
82. Simojoki K, Alho H. A five-year follow-up of buprenorphine abuse potential. J Alcohol Drug Depend 2013;1:1-6.
83. Singh RA, Mattoo SK, Malhotra A, et al. Cases of buprenorphine abuse in India. Acta Psychiatr Scand 1992;86:46-48.
84. Stitzer ML, Vandrey R. Contingency management: utility in the treatment of drug abuse disorders. Clin Pharmacol Ther 2008;83:644-647.
85. Stoller KB, Bigelow GE, Walsh SL, et al. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) 2001;154:230-242.
86. Stover H. Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res 2011;17:44-54.
87. Strain EC, Preston KL, Liebson IA, et al. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther 1992;261:985-993.
88. Strain EC, Stoller K, Walsh SL, et al. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology (Berl) 2000;148:374-383.
89. ThirionX, Lapierre V, Micallef J, et al. Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend 2002;65:197-204.
90. Tkacz J, Severt J, Cacciola J, et al. Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. Am J Addict 2012;21:55-62.
91. Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998;22:430-434.
92. Tuten M, Jones HE, Svikis DS. Comparing homeless and domiciled pregnant substance dependent women on psychosocial characteristics and treatment outcomes. Drug Alcohol Depend 2003;69:95-99.
93. Uosukainen H, Bell JS, Laitinen K, et al. First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland. Int J Drug Policy 2013a;24:492-497.
94. Uosukainen H, Kauhanen J, Bell JS, et al. Mortality among clients seeking treatment for buprenorphine abuse in Finland. Drug Alcohol Depend 2013b;133:391-397.
95. Uosukainen H, Kauhanen J, Voutilainen S, et al. Twelve-year trend in treatment seeking for buprenorphine abuse in Finland. Drug Alcohol Depend 2013c;127:207-214.
96. Vicknasingam B, Mazlan M, Schottenfeld RS, et al. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia. Drug Alcohol Depend 2010;111:44-49.
97. Vidal-Trecan G, Varescon I, Nabet N, et al. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003;69:175-181.
98. Vignau J, Duhamel A, Catteau J, et al. Practice-based buprenorphine maintenance treatment (BMT): how do French healthcare providers manage the opiate-addicted patients? J Subst Abuse Treat 2001;21:135-144.
99. Waller BF, Brownlee WJ, RobertsWC. Self-induced pulmonary granulomatosis. A consequence of intravenous injection of drugs intended for oral use. Chest 1980;78:90-94.
100. Walsh SL, June HL, Schuh KJ, et al. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl) 1995;119:268-276.
101. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55:569-580.